Further investigation of the expression and functional properties of GPC3 isoforms in the context of CAR-NK immunotherapy may provide valuable insights into their role in determining the outcomes of immunotherapeutic approaches targeting GPC3 and other antigens with alternative splicing isoforms, and potentially guide the development of more effective CAR-NK therapies for cancer treatment. Here, GPC3 is linked to cancer.